In Brief This Week: Illumina; Accelerate Diagnostics; Massachusetts Life Sciences Center | GenomeWeb

NEW YORK (GenomeWeb News) – Illumina this week declared conformity with the requirements of the IVD Directive and has applied the CE mark for the MiSeqDx Cystic Fibrosis System. It added that it is finalizing plans to launch the product in "a number" of European countries that require CE marking. The system comprises Illumina's MiSeq benchtop next-generation sequencing instrument, two assays — the MiSeqDx Cystic Fibrosis Diagnostic Assay and the MiSeqDx Cystic Fibrosis Carrier Screening Assay — and associated software. The system is available for order in Europe beginning this month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.